What changed: Post-transplant lymphoproliferative disorder (PTLD)
Every dated change on the records linked to Post-transplant lymphoproliferative disorder (PTLD), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2022 · 2
- 2022ApprovalTabelecleucelTabelecleucel approved in EU
Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy
- 2022MilestoneAllogeneic (off-the-shelf) cell therapyTabelecleucel approved in the EU
First allogeneic T-cell immunotherapy approved; December 2022, for relapsed or refractory EBV-positive PTLD.
2021 · 1
2017 · 2
- 2017GuidelinePost-transplant lymphoproliferative disorder (PTLD)Guideline NCCN Guidelines: B-Cell Lymphomas (PTLD); PTLD-1 RSST (JCO 2017): CD20-positive PTLD not responding to reduced immunosuppression
Rituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment). (NCCN Category 2A)
- 2017MilestoneRituximabRisk-stratified sequential treatment
Rituximab consolidation alone for complete responders (JCO 2017).